ロード中...
A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors
Background This phase 1, single-center, nonrandomized, single-arm, open-label, dose-escalation study, evaluated the tolerability of crenigacestat, a γ-secretase inhibitor as an oral Notch inhibitor in Japanese patients with advanced solid tumors. Methods The study consisted of 2 dose levels of creni...
保存先:
| 出版年: | Invest New Drugs |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7960611/ https://ncbi.nlm.nih.gov/pubmed/32939607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-01001-5 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|